Lantheus Announces Closing of SPECT Business Sale to SHINE Technologies
Rhea-AI Summary
Lantheus (NASDAQ: LNTH) announced on January 2, 2026 that it has completed the sale of its SPECT business to SHINE Technologies. The divestiture transfers the SPECT diagnostic agents TechneLite, NEUROLITE, Xenon Xe-133, and Cardiolite, the portion of the North Billerica, Massachusetts campus that manufactures SPECT products, and SPECT-related Canadian operations to SHINE.
With the SPECT business closed, Lantheus will concentrate on its commercial PET radiodiagnostics and microbubbles and continue advancing its radiopharmaceutical pipeline. Financial, legal, and tax advisors to Lantheus on the transaction were disclosed.
Positive
- Completed sale of SPECT business to SHINE Technologies on Jan 2, 2026
- Sale transfers four named SPECT diagnostic agents to buyer
- Enables focus on PET radiodiagnostics and microbubbles and pipeline advancement
Negative
- Lantheus no longer owns the SPECT product portfolio including TechneLite, NEUROLITE, Xenon Xe-133, and Cardiolite
- SPECT-related manufacturing at the North Billerica campus and Canadian SPECT operations were transferred to SHINE
News Market Reaction – LNTH
On the day this news was published, LNTH gained 1.08%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
LNTH was down 0.91% while peers were mixed: ALKS +0.11%, INDV +0.50%, AMRX -1.95%, PBH -0.40%, HCM 0.00%, suggesting a stock-specific move rather than a sector-wide trend.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Nov 24 | Conference data update | Neutral | +1.2% | Presentation of florbetaben F 18 data at CTAD 2025 conference. |
| Nov 06 | Earnings and guidance | Positive | -6.2% | Q3 2025 results with strong revenue, cash flow and raised full-year guidance. |
| Nov 06 | Leadership transition | Negative | -6.2% | CEO retirement, executive chair assuming interim CEO role, and president departure. |
| Oct 30 | Regulatory milestone | Positive | -0.7% | FDA set PDUFA date for LNTH-2501 PET diagnostic kit for SSTR+ NETs. |
| Oct 28 | NDA acceptance | Positive | -1.4% | FDA accepted MK-6240 NDA for tau PET imaging in Alzheimer’s disease. |
Recent positive regulatory and pipeline updates often saw muted or negative next-day price reactions, suggesting a pattern of selling or indifference on good news.
Over the last few months, Lantheus has focused on expanding its PET imaging and radiopharmaceutical pipeline while managing leadership changes. Key events included FDA acceptance of the MK-6240 NDA with a PDUFA date of Aug 13, 2026, a PDUFA date for LNTH-2501 on Mar 29, 2026, and Q3 2025 revenue of $384.0M with updated full-year guidance. Despite these milestones, several positive or neutral announcements were followed by flat to negative price moves, providing context for how investors previously reacted to strategic updates like today’s SPECT divestiture.
Market Pulse Summary
This announcement finalizes the sale of Lantheus’ SPECT business, including several legacy diagnostic agents and related manufacturing assets, to SHINE Technologies. The transaction follows earlier classification of the SPECT unit as held for sale and supports Lantheus’ focus on its PET radiodiagnostics and microbubble portfolio. Investors may track execution around the core PET pipeline, the performance of recently acquired imaging assets, and how management deploys resources freed up by this divestiture.
Key Terms
single photon emission computed tomography medical
radiopharmaceuticals medical
nasolacrimal drainage system medical
myocardial perfusion medical
radiopharmaceuticals medical
AI-generated analysis. Not financial advice.
BEDFORD, Mass., Jan. 02, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company dedicated to helping clinicians Find, Fight, and Follow disease to deliver better patient outcomes, today announced it has completed the previously announced sale of its single photon emission computed tomography (SPECT) business to SHINE Technologies, LLC, a subsidiary of Illuminated Holdings, Inc. (collectively, “SHINE”). Under the terms of the agreement, SHINE has acquired Lantheus’ SPECT business, including its diagnostic agents (TechneLite® (Technetium Tc 99m generator), NEUROLITE® (Kit for the Preparation of Technetium Tc 99m Bicisate for Injection), Xenon Xe-133 Gas (Xenon Xe-133 Gas), and Cardiolite® (Kit for the Preparation of Technetium Tc99m Sestamibi for Injection)), the portion of the North Billerica, Massachusetts campus that manufactures Lantheus’ SPECT products, and the SPECT-related Canadian operations.
With the SPECT divestiture finalized, Lantheus will focus on its growing commercial portfolio of innovative PET radiodiagnostics and microbubbles, while also advancing its pipeline of radiopharmaceuticals.
Advisors
Solomon Partners Securities, LLC acted as financial advisor to Lantheus in this transaction, while Foley Hoag LLP and Ropes & Gray LLP acted as legal advisors, and Ernst & Young LLP acted as financial and tax advisor.
TechneLite® (Technetium Tc 99m generator)
INDICATIONS AND USAGE:
The TechneLite® generator is a source of sodium pertechnetate Tc 99m for use in the preparation of FDA-approved diagnostic radiopharmaceuticals, as described in the labeling of these diagnostic radiopharmaceutical kits.
Sodium Pertechnetate Tc 99m Injection is used IN ADULTS as an agent for:
- Thyroid Imaging
- Salivary Gland Imaging
- Urinary Bladder Imaging (direct isotopic cystography) for the detection of vesico-ureteral reflux.
- Nasolacrimal Drainage System Imaging
Sodium Pertechnetate Tc 99m Injection is used IN CHILDREN as an agent for:
- Thyroid Imaging
- Urinary Bladder Imaging (direct isotopic cystography) for the detection of vesico-ureteral reflux.
IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS:
None known.
IMPORTANT SAFETY INFORMATION:
Allergic reactions including anaphylaxis have been reported infrequently following the administration of Sodium Pertechnetate Tc 99m Injection.
WARNINGS
Radiation risks associated with the use of Sodium Pertechnetate Tc 99m Injection are greater in children than in adults and, in general, the younger the child, the greater the risk owing to greater absorbed radiation doses and longer life expectancy.
These greater risks should be taken firmly into account in all benefit-risk assessments involving children. Long-term cumulative radiation exposure may be associated with an increased risk of cancer.
PRECAUTIONS
Since the eluate does not contain an antimicrobial agent, it should not be used after 12 hours from the time of TechneLite®, Technetium Tc 99m Generator, elution. After the termination of the nasolacrimal imaging procedure, blowing the nose and washing the eyes with sterile distilled water or an isotonic sodium chloride solution will further minimize the radiation dose. As in the use of any radioactive material, care should be taken to minimize radiation exposure to patients and occupational workers. Radiopharmaceuticals should be used only by physicians who are qualified by training and experience and who are licensed in the safe handling of radionuclides.
Please see full Prescribing Information.
Xenon (Xenon Xe-133 Gas)
INDICATIONS AND USAGE
Inhalation of Xenon Xe-133 Gas has proved valuable for the evaluation of pulmonary function and for imaging the lungs. It may also be applied to assessment of cerebral flow.
IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS
None known.
Adverse reactions related to the use of this agent have not been reported to date.
WARNINGS
Xenon Xe-133 Gas delivery systems, i.e., respirators or spirometers, and associated tubing assemblies must be leak-proof to avoid loss of radioactivity into environs not specifically protected by exhaust systems.
Xenon Xe-133 adheres to some plastics and rubber and should not be allowed in tubing or respirator containers. The unrecognized loss of radioactivity from the dose for administration may render the study non-diagnostic.
The vial stopper contains dry natural rubber latex and may cause allergic reactions in providers or patients who are sensitive to latex.
PRECAUTIONS
General
Xenon Xe-133, as well as other radioactive drugs, must be handled with care and appropriate safety measures should be used to minimize radiation exposure to patients and to clinical personnel.
Radiopharmaceuticals should be used only by physicians who are qualified by training and experience in the safe use and handling of radionuclides and whose experience and training have been approved by the appropriate government agency authorized to license the use of radionuclides.
Please see full Prescribing Information.
NEUROLITE® (Kit for the Preparation of Technetium Tc 99m Bicisate for Injection)
INDICATIONS
NEUROLITE® single photon emission computerized tomography (SPECT) is indicated as an adjunct to conventional CT or MRI imaging in the localization of stroke in patients in whom stroke has already been diagnosed.
NEUROLITE® is not indicated for assessment of functional viability of brain tissue or for distinguishing between stroke and other brain lesions.
IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS
None known.
In clinical trials, NEUROLITE® has been administered to 1063 subjects (255 normals, 808 patients). In the 808 patients with neurologic events, there were 11 (
The following adverse effects were observed in ≤
WARNINGS
None known.
PRECAUTIONS
General
USE WITH CAUTION IN PATIENTS WITH RENAL OR HEPATIC IMPAIRMENT. TECHNETIUM Tc99m BICISATE IS ELIMINATED PRIMARILY BY RENAL EXCRETION. WHETHER TECHNETIUM Tc99m BICISATE IS DIALYZABLE IS NOT KNOWN. DOSE ADJUSTMENTS IN PATIENTS WITH RENAL OR HEPATIC IMPAIRMENT HAVE NOT BEEN STUDIED.
Patients should be encouraged to drink fluids and to void frequently during the 2-6 hours immediately after injection to minimize radiation dose to the bladder and other target organs.
As with any other radioactive material, appropriate shielding should be used to avoid unnecessary radiation exposure to the patient, occupational workers, and other people.
Radiopharmaceuticals should be used only by physicians who are qualified by specific training in the safe use and handling of radionuclides.
Please see full Prescribing Information.
Cardiolite® (Kit for the Preparation of Technetium Tc99m Sestamibi for Injection)
INDICATIONS AND USAGE
Myocardial Imaging: Cardiolite® (Kit for the Preparation of Technetium Tc99m Sestamibi for Injection), is a myocardial perfusion agent that is indicated for detecting coronary artery disease by localizing myocardial ischemia (reversible defects) and infarction (non-reversible defects), in evaluating myocardial function and developing information for use in patient management decisions. Cardiolite® evaluation of myocardial ischemia can be accomplished with rest and cardiovascular stress techniques (e.g. exercise or pharmacologic stress in accordance with the pharmacologic stress agent’s labeling).
It is usually not possible to determine the age of a myocardial infarction or to differentiate a recent myocardial infarction from ischemia.
Breast Imaging: MIRALUMA®, Kit for the Preparation of Technetium Tc99m Sestamibi for Injection, is indicated for planar imaging as a second line diagnostic drug after mammography to assist in the evaluation of breast lesions in patients with an abnormal mammogram or a palpable breast mass.
MIRALUMA® is not indicated for breast cancer screening, to confirm the presence or absence of malignancy, and it is not an alternative to biopsy.
IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS
None known.
Cardiolite® has been rarely associated with acute severe allergic and anaphylactic events of angioedema and generalized urticaria. In some patients the allergic symptoms developed on the second injection during Cardiolite® imaging. The most frequently reported adverse events include headache, chest pain/angina, ST segment changes on ECG, nausea, and abnormal taste and smell.
Infrequently, death has occurred 4 to 24 hours after Tc99m Sestamibi use and is usually associated with exercise stress testing (See Section 5.2). Pharmacologic induction of cardiovascular stress may be associated with serious adverse events such as myocardial infarction, arrhythmia, hypotension, bronchoconstriction and cerebrovascular events.
WARNINGS AND PRECAUTIONS
In studying patients in whom cardiac disease is known or suspected, care should be taken to assure continuous monitoring and treatment in accordance with safe, accepted clinical procedure.
Caution should be exercised and emergency equipment should be available when administering Cardiolite®.
Before administering Cardiolite® patients should be asked about the possibility of allergic reactions to either Cardiolite® or Miraluma®. Miraluma® is an identical compound used in breast imaging.
The contents of the vial are intended only for use in the preparation of Technetium Tc99m Sestamibi and are not to be administered directly to the patient without first undergoing the preparative procedure.
Please see full Prescribing Information.
About Lantheus
Lantheus is the leading radiopharmaceutical-focused company, delivering life-changing science to enable clinicians to Find, Fight and Follow disease to deliver better patient outcomes. Headquartered in Massachusetts with offices in New Jersey, Canada, Germany, Sweden, Switzerland, and the United Kingdom, Lantheus has been providing radiopharmaceutical solutions for 70 years. For more information, visit www.lantheus.com.
About SHINE Technologies, LLC
Headquartered in Janesville, Wisconsin, SHINE is an industry leader in next-generation fusion, developing innovative fusion-based technology that combines safety, cost-efficiency and environmental responsibility.
SHINE has successfully commercialized fusion across multiple applications, including neutron testing markets such as neutron radiography, radiation-effects testing and fusion material research. It has commercialized and is scaling its proprietary medical isotope production, supplying high-quality radioisotopes essential for procedures involving diagnosis of heart disease and cancer and therapeutic cancer treatments.
Beyond these applications, SHINE is pioneering nuclear waste recycling to make nuclear energy more sustainable. Its long-term purpose is to change the way humans make energy by commercializing fusion energy. Unlike other fusion companies, SHINE takes a commercially driven path mirroring successful deep-tech industries. Through this visionary approach, SHINE is advancing technology, healthcare, and sustainable energy, making a lasting impact across multiple sectors.
Contacts:
Mark Kinarney
Vice President, Investor Relations
978-671-8842
ir@lantheus.com
Melissa Downs
Executive Director, External Communications
646-975-2533
media@lantheus.com
FAQ
Who bought Lantheus SPECT business and when was the deal completed (LNTH)?
Which SPECT products did Lantheus sell in the SHINE transaction (LNTH)?
What operations were transferred with the SPECT sale by Lantheus (LNTH)?
How will the SPECT divestiture change Lantheus' strategic focus (LNTH)?
Did Lantheus disclose advisers for the SPECT business sale (LNTH)?
